文献速递膀胱癌与上尿路尿路上皮癌

抗生素使用与阿替利珠单抗治疗尿路上皮癌的生存关联

Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
PubMed 文献 · Eur Urol · 2020-07-11

基于IMvigor210和IMvigor211的事后分析,评估抗生素使用与阿替利珠单抗或化疗患者生存的关联。抗生素使用与阿替利珠单抗更差的总生存(HR 1.44,95%CI 1.19-1.73)和无进展生存(HR 1.24,95%CI 1.05-1.46)相关,而化疗组无此关联。

要点

  • 抗生素使用与阿替利珠单抗治疗患者的OS和PFS显著更差相关。
  • 化疗组中未观察到抗生素使用与生存的显著关联。
  • 该关联在PD-L1 IC2/3人群中也类似,但研究不足以改变感染抗生素选择。

核心结论

  • 抗生素使用与阿替利珠单抗治疗的尿路上皮癌患者更差的总生存和无进展生存相关。
  • 化疗组中未观察到抗生素使用与生存的显著关联,提示抗生素可能特异性降低免疫治疗疗效。

研究设计与样本

  • IMvigor210(单臂阿替利珠单抗)和IMvigor211(阿替利珠单抗对比化疗的III期随机试验)的事后分析。
  • 抗生素使用定义为治疗开始前30天至开始后30天内任何抗生素给药。
  • 采用Cox比例风险分析评估抗生素使用与总生存和无进展生存的关联。

主要发现

  • 阿替利珠单抗组中,抗生素使用与更差的总生存相关(n=847,HR 1.44,95%CI 1.19-1.73)。
  • 阿替利珠单抗组中,抗生素使用与更差的无进展生存相关(HR 1.24,95%CI 1.05-1.46)。
  • 化疗组中,抗生素使用与总生存(n=415,HR 1.15,95%CI 0.91-1.46)和无进展生存(HR 1.09,95%CI 0.88-1.36)无显著关联。
  • IMvigor211随机队列中,抗生素使用者阿替利珠单抗对比化疗的总生存HR为0.95(95%CI 0.71-1.25),非使用者为0.73(95%CI 0.60-0.88),交互作用P=0.1。
  • PD-L1 IC2/3人群中观察到类似关联。

临床怎么用

  • 研究结果不足以改变感染时的抗生素选择。
  • 癌症治疗中抗生素过度使用需在免疫检查点抑制剂背景下评估。

局限性

  • 为事后分析,证据级别有限。
  • 抗生素使用与生存的关联可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotic effects on the gut microbiota may negatively impact survival with immune checkpoint inhibitors (ICIs). However, there is minimal evidence regarding whether antibiotic impacts are specific to ICIs or impacts in urothelial carcinoma (UC). In a post hoc analysis of IMvigor210 (single-arm atezolizumab) and IMvigor211 (phase III randomised trial of atezolizumab vs chemotherapy), the association between antibiotic use and overall survival (OS) and progression-free survival (PFS) was assessed via Cox proportional hazard analysis. Antibiotic use was defined as any antibiotic administration between 30 d prior to and 30 d after treatment initiation. Antibiotic use was associated with worse OS (n = 847, hazard ratio or HR [95% confidence interval {CI}] = 1.44 [1.19-1.73]) and PFS (1.24 [1.05-1.46]) with atezolizumab, but not chemotherapy (n = 415, 1.15 [0.91-1.46] and 1.09 [0.88-1.36], respectively). In the randomised cohort of IMvigor211, the OS treatment effect (HR [95% CI]) of atezolizumab versus chemotherapy was 0.95 (95% CI 0.71-1.25) for antibiotic users, compared with 0.73 (0.60-0.88) for nonusers (p[interaction] = 0.1). Similar associations were noted in the PD-L1 IC2/3 population. In conclusion, antibiotic use was associated with worse survival outcomes in UC patients treated with atezolizumab. The study does not justify a change in antibiotic selection for infections; however antibiotic overuse occurs in cancer care and this needs to be evaluated for ICIs. PATIENT SUMMARY: In this report from clinical trials IMvigor210 and IMvigor211, it was demonstrated that antibiotic use is consistently associated with worse survival in patients with urothelial carcinoma treated with atezolizumab. No antibiotic association was observed in patients treated with chemotherapy, suggesting that antibiotics may specifically reduce the effectiveness of cancer immunotherapies. Future research will continue to explore the effect of antibiotics on other immune checkpoint inhibitors and confirm whether immune checkpoint inhibitors remain the treatment of choice in cancer patients requiring antibiotics.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hopkins AM, Kichenadasse G, Karapetis CS, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol. 2020. PMID: 32660748. doi:10.1016/j.eururo.2020.06.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。